Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The α4β2 nicotinic acetylcholine receptor (α4β2 nAChR) is a pentameric ligand-gated ion channel composed of alpha-4 (CHRNA4) and beta-2 (CHRNB2) subunits. It is the most abundant nicotinic receptor subtype in the mammalian brain and plays a central role in mediating the effects of nicotine, including its addictive properties. The receptor is implicated in cognitive processes such as learning and attention, as well as growth hormone secretion. Upon binding acetylcholine or agonists like nicotine, the receptor undergoes conformational changes that open its ion channel, allowing Na^+ and K^+ ions to flow across neuronal membranes. This leads to neuronal excitation both pre-synaptically and post-synaptically. Activation enhances neurotransmitter release and modulates synaptic plasticity. Mutations in CHRNA4 have been linked with autosomal dominant nocturnal frontal lobe epilepsy and paroxysmal kinesogenic dyskinesia.
Agonist-induced opening of cation channel allowing Na^+ and K^+ influx, leading to neuronal excitation; partial agonism modulating receptor activity.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinic Acetylcholine Receptor Subunit Alpha-4 Beta-2 (α4β2 nAChR).